FDA Approves Takeda’s EoE Therapy EOHILIA
FDA approves Takeda's EOHILIA as first-line treatment for Eosinophilic Esophagitis. Groundbreaking oral therapy offers hope for improved quality of life.
- Latest
- Trending
FDA approves Takeda's EOHILIA as first-line treatment for Eosinophilic Esophagitis. Groundbreaking oral therapy offers hope for improved quality of life.
T2 Biosystems has received FDA clearance to update its T2Bacteria Panel, expanding its coverage of sepsis-causing pathogens and potentially leading ...
Cidara Therapeutics receives $11.1 million milestone payment from Mundipharma for European approval of new antifungal drug, Rezzayo. Analysts see potential ...
The use of robotic-assisted surgery and surgical navigation techniques does not increase the risk of joint infection in total hip ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.